Trust Signals
This page was written by the FormBlends Medical Team, cross-referenced against PubMed-indexed clinical trials, FDA approval records, and published pharmacokinetic data. Every evidence confidence rating is based on study design and sample size, not marketing copy. Claims are separated by evidence grade throughout. This page does not sell products and does not receive affiliate revenue from peptide vendors.
Key Takeaways
- Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved therapeutic peptides with phase 3 trial data showing 15 to 21 percent body weight reduction over 68 to 72 weeks.
- CJC-1295 and ipamorelin are the most studied research-phase GH-axis peptides, but no published human RCT tests them specifically for weight loss as a primary endpoint.
- AOD-9604 failed its pivotal phase 2b/3 human weight-loss trial (METAOD, n=511) and was abandoned by its developer for the obesity indication.
- Peptide purity varies enormously across vendors; a certificate of analysis without third-party mass spectrometry confirmation is insufficient to verify identity.
- Weight regain after stopping semaglutide averages roughly two-thirds of lost weight within one year without lifestyle maintenance, per the STEP 4 withdrawal trial (n=803).
What Are the Best Peptides for Weight Loss? Direct Answer
The best peptides for weight loss by clinical evidence are semaglutide and tirzepatide, both FDA-approved GLP-1-based agents with large phase 3 trials behind them. For research-phase options, CJC-1295 combined with ipamorelin has the strongest pharmacodynamic rationale. Every other candidate currently sits at animal or mechanistic evidence only.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Ranked list: which peptides have the strongest evidence?
- Evidence ledger: grading every major claim
- How do weight-loss peptides actually work? Mechanism with numbers
- What most pages get wrong about peptides for fat loss
- Honest head-to-head: peptides vs. real alternatives
- Chemistry behind the rules: why storage and stability matter
- Operational label literacy: how to read a COA and judge a product
- Dosing reference table (research context)
- Frequently asked questions
- Sources
Ranked List: Which Peptides Have the Strongest Evidence for Weight Loss?
Tier 1: FDA-approved, phase 3 RCT evidence
Semaglutide (Ozempic / Wegovy). A 31-amino-acid GLP-1 analogue. The STEP 1 trial (Wilding et al., NEJM 2021, n=1,961) showed 14.9 percent mean body weight reduction at 68 weeks with 2.4 mg weekly subcutaneous dosing against placebo plus lifestyle intervention. This is the reference standard for peptide-based weight loss.
Tirzepatide (Mounjaro / Zepbound). A 39-amino-acid dual GLP-1 and GIP receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, n=2,539) showed up to 20.9 percent mean body weight reduction at 72 weeks with 15 mg weekly dosing. Currently the highest-effect-size approved weight-loss agent in this class.
Tier 2: Research-phase, pharmacodynamic data in humans, no weight-loss RCT
CJC-1295 with or without DAC. A GHRH analogue. A phase 1/2 study (Teichman et al., JCEM 2006, n=65) confirmed dose-dependent increases in mean GH concentration (2-fold to 10-fold over baseline, dose-dependent) and sustained IGF-1 elevation. No published RCT uses weight change as a primary endpoint.
Ipamorelin. A selective GHRP-2 analogue. Human pharmacokinetic data confirm GH pulse induction. Preclinical data show body composition effects at GH-axis level. No published human weight-loss trial.
Tier 3: Animal data or failed human trials
AOD-9604. Fragment 176-191 of the hGH C-terminus. Animal studies showed beta-3 adrenergic receptor-mediated lipolysis. The METAOD phase 2b/3 trial (Heffernan et al., published results available via ClinicalTrials.gov NCT00174668, n=511) failed to demonstrate significant weight loss versus placebo. Developer Monash University and Metabolic Pharmaceuticals ceased the obesity program.
5-amino-1MQ. A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), technically not a peptide. Mouse data (Kannt et al., related NNMT literature) show improved metabolic parameters. No human trial data published as of this writing.
Evidence Ledger: Grading Every Major Claim
| Claim | Best Evidence Type | Key Source / Trial | Effect Direction | Confidence |
|---|---|---|---|---|
| Semaglutide 2.4 mg causes ~15% body weight loss in adults with obesity | Phase 3 RCT (n=1,961) | STEP 1, Wilding et al., NEJM 2021 | Strong positive | High |
| Tirzepatide 15 mg causes ~21% body weight loss | Phase 3 RCT (n=2,539) | SURMOUNT-1, Jastreboff et al., NEJM 2022 | Strong positive | High |
| CJC-1295 raises mean GH 2-10x over baseline | Phase 1/2 human PK study (n=65) | Teichman et al., JCEM 2006 | Positive for GH, not for weight | Moderate (for GH endpoint only) |
| Ipamorelin selectively raises GH without cortisol spike | Human PK / animal studies | Multiple pharmacology papers | Positive for GH selectivity | Moderate |
| AOD-9604 reduces body weight in humans | Phase 2b/3 RCT (n=511) | METAOD trial, NCT00174668 | Null (no significant difference) | High confidence in failure |
| GH elevation from CJC-1295/ipamorelin reduces fat mass in humans | Mechanism inference from GH physiology | No dedicated weight-loss RCT | Plausible but unproven | Very Low |
| Weight regain after stopping semaglutide is approximately two-thirds within one year | Phase 3 withdrawal RCT (n=803) | STEP 4, Rubino et al., JAMA 2021 | Negative (weight regain) | High |
How Do Weight-Loss Peptides Actually Work? Mechanism with Numbers
GLP-1 receptor agonists (semaglutide, tirzepatide GLP-1 arm)
GLP-1 receptors are expressed on pancreatic beta cells, vagal afferents, and hypothalamic neurons including the arcuate nucleus. Receptor activation suppresses glucagon secretion, slows gastric emptying (measured in scintigraphy studies as delayed time to half-emptying), and reduces food intake via hypothalamic appetite circuits. Semaglutide's C18 fatty diacid chain bound at lysine-26 enables reversible albumin binding, extending its plasma half-life to approximately 7 days, versus native GLP-1's half-life of under 2 minutes. This prolonged receptor occupancy is the pharmacokinetic basis for once-weekly dosing.
Tirzepatide adds GIP receptor agonism. GIP receptors are highly expressed in adipose tissue and potentiate insulin secretion in a glucose-dependent manner. The combined receptor activation appears to produce additive or synergistic appetite suppression and energy expenditure effects, which explains the larger weight-loss effect size seen in SURMOUNT-1 versus STEP 1, though these were separate trials with different populations.
Important caveat: GLP-1 mechanism does not prove the weight loss is durable without ongoing treatment. STEP 4 withdrawal data make clear the mechanism requires continuous receptor engagement.
GH-axis peptides (CJC-1295, ipamorelin)
CJC-1295 binds GHRH receptors on anterior pituitary somatotrophs. The DAC (drug affinity complex) version covalently binds albumin via a maleimide reaction, extending half-life to approximately 6 to 8 days. The non-DAC version has a half-life of roughly 30 minutes. Ipamorelin activates the ghrelin/growth hormone secretagogue receptor (GHSR-1a), triggering a separate pituitary GH release pathway. Combined use is designed to amplify pulsatile GH output via two independent receptor mechanisms.
Elevated GH increases lipolysis by activating hormone-sensitive lipase in adipocytes and shifts substrate oxidation toward fatty acids. However, GH also causes peripheral insulin resistance. At supraphysiological levels, this can raise fasting glucose, which is a relevant safety consideration that most promotional pages omit entirely.
What Most Pages Get Wrong About Peptides for Fat Loss
This is the section most commodity pages skip entirely. It is the highest-value information on this page.
1. Conflating GH increase with fat loss. CJC-1295 reliably raises GH. GH physiology supports lipolysis. But raising GH in a well-nourished, sedentary person does not automatically produce meaningful fat loss. The GH-to-fat-loss chain requires caloric context. No peer-reviewed weight-loss RCT with CJC-1295 as intervention has been published. The evidence gap is large.
2. AOD-9604 is presented as proven when it failed its pivotal trial. Virtually every listicle ranks AOD-9604 as a legitimate fat-loss peptide. The METAOD trial tested it in over 500 humans and found no significant benefit over placebo. This is not a minor caveat; it is a program-ending result. The compound may still be sold and used, but presenting it as an evidence-backed option is misleading.
3. Bioavailability of oral and topical peptide formulations. Peptides above roughly 500 to 700 daltons have poor gastrointestinal absorption due to enzymatic degradation by peptidases and limited paracellular transport. Semaglutide oral (Rybelsus) achieves only 0.4 to 1 percent bioavailability and requires specific fasting protocols to reach therapeutic exposure. Peptides sold as oral capsules or drops from research vendors typically have no bioavailability data whatsoever. Subcutaneous injection is the delivery route with confirmed pharmacokinetic data for the peptides on this page.
4. Purity claims without mass spectrometry. An HPLC chromatogram showing a single peak does not confirm the peak is the correct peptide, only that the sample is relatively homogeneous. Mass spectrometry (confirming the molecular weight matches the expected peptide) is the minimum to confirm identity. Many vendor COAs show HPLC only.
5. Ignoring IGF-1 implications of long-term GH stimulation. Chronic GH-axis stimulation raises IGF-1. Epidemiological data associate elevated IGF-1 with increased cancer risk in some contexts. This does not prove research-peptide protocols cause cancer, but the risk is uncharacterized and should not be dismissed or unmentioned.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Agent | Class | Best Human Evidence | Mean Weight Loss (humans) | FDA Status | Where Peptide Loses |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 peptide | Phase 3 RCT, n=1,961 | ~14.9% | Approved (Wegovy) | Cost, GI side effects, requires ongoing use |
| Tirzepatide 15 mg | Dual GLP-1/GIP peptide | Phase 3 RCT, n=2,539 | ~20.9% | Approved (Zepbound) | Cost, less long-term cardiovascular data than semaglutide |
| CJC-1295 + ipamorelin | GH-axis research peptides | Phase 1/2 PK studies | Not established in RCT | Not approved | Loses on every clinical evidence metric vs. GLP-1 agents |
| Phentermine-topiramate (Qsymia) | Small molecule combination | Phase 3 RCT (CONQUER, n=2,487) | ~9-10% | Approved | Cardiovascular warnings, teratogenicity risk |
| Orlistat | Lipase inhibitor | Multiple RCTs, Cochrane review | ~3% | Approved (OTC and Rx) | Much lower efficacy than GLP-1 peptides |
| AOD-9604 | hGH fragment research peptide | Phase 2b/3 RCT (failed) | Not significant vs. placebo | Not approved | Loses on the only pivotal human trial that exists |
Chemistry Behind the Rules: Why Storage and Stability Matter
Why lyophilized peptides degrade on reconstitution. Lyophilization (freeze-drying) removes water and arrests most hydrolytic and oxidative degradation pathways. Once a peptide is reconstituted in aqueous solution, several degradation routes reactivate: hydrolysis of peptide bonds (particularly at Asp-Pro sequences, which are more labile), oxidation of methionine and cysteine residues, and deamidation of asparagine residues. These are temperature-dependent reactions that accelerate substantially above 4 degrees Celsius.
Why bacteriostatic water, not sterile water, is the standard reconstitution vehicle. Bacteriostatic water contains 0.9 percent benzyl alcohol, a broad-spectrum antimicrobial that prevents bacterial growth over weeks of refrigerated storage. Sterile water is single-use; reconstituting with it and then multi-dosing over days creates contamination risk. This is not a marketing preference; it reflects basic microbiology of multi-dose vials.
Why freeze-thaw cycles matter. Each freeze-thaw cycle mechanically stresses the peptide chain through ice crystal formation and osmotic changes during thawing. Repeated cycling progressively increases aggregation and fragmentation. The practical rule is: aliquot reconstituted peptide into single-use volumes before freezing if long-term storage is needed. Commodity pages say "don't freeze-thaw repeatedly" without explaining that ice crystal formation is the physical mechanism, which means even a single poorly managed thaw can cause meaningful degradation.
Why CJC-1295 without DAC and with DAC are functionally different products. The DAC modification attaches a maleimide group that forms a covalent thioether bond with cysteine-34 of circulating albumin. This is an irreversible bond under physiological conditions, which is what extends the half-life from roughly 30 minutes to 6 to 8 days. Substituting one version for the other changes the entire dosing interval and steady-state GH profile. They are not interchangeable.
Operational Label Literacy: How to Read a COA and Judge a Product
Minimum acceptable COA elements:
| Element | What to Look For | Red Flag |
|---|---|---|
| Purity (HPLC) | Greater than 98% for research/pharmaceutical grade | "Greater than 95%" with no confirmation method named |
| Identity (MS) | Observed molecular weight matches theoretical within 0.1 Da | HPLC only, no mass spec confirmation |
| Endotoxin testing | LAL (Limulus amebocyte lysate) assay result in EU/mg | No endotoxin data; injectable use without this is high risk |
| Residual solvents | Meets USP Class 2 or 3 limits | Not mentioned at all |
| Issuing lab | Independent third-party lab, named and verifiable | COA issued by the vendor itself or an unidentifiable lab |
| Lot number linkage | COA lot number matches vial label | Generic COA with no lot number or product-specific link |
How to do basic reconstitution math. If a vial contains 5 mg of peptide and you add 2.5 mL of bacteriostatic water, the concentration is 2 mg/mL (2,000 mcg/mL). A 100-mcg dose requires 0.05 mL, which is the 5-unit mark on a U-100 insulin syringe. Work from concentration equals mass divided by volume. Always verify units: vials are labeled in mg, doses are often discussed in mcg, and syringes are calibrated in mL or units.
Dosing Reference Table (Research Context Only)
The following table reflects dosing ranges used in cited research studies or established clinical protocols. It is not a prescription or a recommendation. Research peptides are not approved drugs. Consult a licensed physician before using any of these compounds.
| Peptide | Study/Protocol Dose Range | Route | Frequency | Evidence Basis |
|---|---|---|---|---|
| Semaglutide (Wegovy) | 0.25 mg escalating to 2.4 mg | Subcutaneous injection | Once weekly | FDA-approved label / STEP 1 trial |
| Tirzepatide (Zepbound) | 2.5 mg escalating to 15 mg | Subcutaneous injection | Once weekly | FDA-approved label / SURMOUNT-1 trial |
| CJC-1295 without DAC | 100 to 200 mcg per injection | Subcutaneous injection | 1 to 2 times daily | Pharmacology literature; no weight-loss RCT |
| Ipamorelin | 100 to 300 mcg per injection | Subcutaneous injection | 1 to 3 times daily | Pharmacology literature; no weight-loss RCT |
| AOD-9604 | 1 mg/day used in METAOD trial | Subcutaneous injection | Once daily | METAOD trial (failed primary endpoint) |
Frequently Asked Questions
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1 trial)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1 trial)
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
- ClinicalTrials.gov. AOD9604 in Obese Adults (METAOD). NCT00174668. Metabolic Pharmaceuticals.
- Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000;24(3):288-298.
- FDA. Wegovy (semaglutide) Prescribing Information. NDA 215256. U.S. Food and Drug Administration. 2021.
- FDA. Zepbound (tirzepatide) Prescribing Information. NDA 217806. U.S. Food and Drug Administration. 2023.
- Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
- Bloom SR, Kuhajda FP, Laher I, et al. The obesity epidemic: pharmacological challenges. Mol Interv. 2008;8(2):82-98. (GH and lipolysis mechanism context)